ARCHIVES

Tamoxifen Listed By IARC Report As Carcinogen CTRF Seeks Applicants

This article is from The Cancer Letter archive.

Vol. 22 No. 09 | March 1, 1996

Download PDF Visit The Full Archive

Related Articles

Intramural Funding To Decrease, R01s Increase, Klausner Says

September 15, 1995

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002

In Brief: Pazdur to direct FDA Oncology Division; Ganz Awarded ACS Clinical Professorship

July 23, 1999

Consensus Conference agrees That Nevi Can Be Precursors For Melanoma, Offers Management Suggestions

November 4, 1983

House Members Express Support for Cancer Program

September 12, 1980

Cancer Centers Could Form Network for Genetics Research, NCI Says

April 12, 1996